Cigarette smoke retention and bronchodilation in patients with COPD. A controlled randomized trial  by van Dijk, Wouter D. et al.
Respiratory Medicine (2013) 107, 112e119Available online at www.sciencedirect.com
journal homepage: www.elsevier .com/locate /rmedCigarette smoke retention and
bronchodilation in patients with COPD.
A controlled randomized trialWouter D. van Dijk a,*, Yvonne Heijdra b, Jacques W.M. Lenders c,d,
Walther Klerx e, Reinier Akkermans a, Anouschka van der Pouw f,
Chris van Weel a, Paul T.J. Scheepers g, Tjard R.J. Schermer aaDepartment of Primary and Community Care, Radboud University Nijmegen Medical, Centre, Geert Grooteplein Noord 21,
Route 117 e ELG, Nijmegen, The Netherlands
bDepartment of Pulmonary Diseases, Radboud, University Nijmegen Medical Centre, Nijmegen, The Netherlands
cDepartment of Internal, Medicine, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
dDepartment of Internal Medicine III, University Hospital Carl Gustav Carus, Dresden, Germany
e Food and Consumer Product Safety Authority, Eindhoven, The Netherlands
fDepartment of Pulmonary Diseases, Alysis Medical Centre, Arnhem, The Netherlands
gDepartment of Epidemiology, Biostatistics and HTA, Radboud University Nijmegen Medical Centre, Nijmegen,
The Netherlands
Received 23 December 2011; accepted 12 September 2012
Available online 12 October 2012KEYWORDS
COPD;
Interaction;
Smoke retention;
Smoking* Corresponding author. Tel.: þ31 0
E-mail addresses: w.vandijk@aio
Lenders), w.klerx@vwa.nl (W. Klerx),
elg.umcn.nl (C. van Weel), p.scheepe
0954-6111 ª 2012 Elsevier Ltd.
http://dx.doi.org/10.1016/j.rmed.20
Open aSummary
Introduction: Bronchodilators are the cornerstone for symptomatic treatment of chronic
obstructive pulmonary disease (COPD). Many patients use these agents while persisting in their
habit of cigarette smoking. We hypothesized that bronchodilators increase pulmonary reten-
tion of cigarette smoke and hence the risk of smoking-related (cardiovascular) disease. Our
aim was to investigate if bronchodilation causes increased pulmonary retention of cigarette
smoke in patients with COPD.
Methods: A double-blinded, placebo-controlled, randomized crossover trial, in which COPD
patients smoked cigarettes during undilated conditions at one session and maximal bronchodi-
lated conditions at the other session. Co-primary outcomes were pulmonary tar and nicotine
retention. We performed a secondary analysis that excludes errors due to possible contamina-
tion. Secondary outcomes included the biomarkers C-reactive protein and fibrinogen, and
smoke inhalation patterns.243614611.
s.umcn.nl (W.D. van Dijk), y.heijdra@long.umcn.nl (Y. Heijdra), J.Lenders@aig.umcn.nl (J.W.M.
r.akkermans@elg.umcn.nl (R. Akkermans), avanderpouw@alysis.nl (A. van der Pouw), c.vanweel@
rs@ebh.umcn.nl (P.T.J. Scheepers), t.schermer@elg.umcn.nl (T.R.J. Schermer).
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ccess under the Elsevier OA license.
Smoke retention and bronchodilation in COPD 113Results: Of 39 randomized patients, 35 patients completed the experiment and were included
in the final analysis. Bronchodilation did not significantly increase tar retention (4.5%,
p Z 0.20) or nicotine retention (2.6%, p Z 0.11). Secondary analysis revealed a potential
reduction of retention due to bronchodilation: tar retention (3.8%, p Z 0.13), and nicotine
retention (3.4%, p Z 0.01). Bronchodilation did not modify our secondary outcomes.
Conclusions: Our results do not support the hypothesis that cigarette tar and nicotine reten-
tion in COPD patients is increased by bronchodilation, whereas we observed a possibility
towards less retention.
Trial registration: www.clinicaltrials.gov: NCT00981851.
ª 2012 Elsevier Ltd.Open access under the Elsevier OA license.Introduction
Chronic obstructive pulmonary disease (COPD) is a highly
prevalent chronic condition, characterized by debilitating
and progressive airflow obstruction.1 Unlike cardiovascular
disease and other chronic conditions, prevalence and
mortality of COPD still increase globally.1e3 In addition,
patients with COPD often suffer from co-morbidity (cardio-
vascular disease; lung cancer) that contributes to
mortality.4,5 Apart froman independent association between
COPD and cardiovascular disease, both diseases share
a common risk factor, i.e. cigarette smoking.1,6,7 Whereas
approximately 90% of COPD is caused by smoking, about 50%
of patients with diagnosed COPD continue to smoke, often
despite intensive smoking cessation programs.7e9
Bronchodilators are the cornerstone of the pharmaco-
therapeutic management of COPD patients, with a current
trend towards the use of long-acting and ultra long-acting
drugs.1,8,10 However, there is a controversy about the
safety of bronchodilators, which in particular concerns
their cardiovascular effects.11 Recent large randomized
controlled trials observed a possible protective effect on
(cardiovascular) mortality, but meta-analyses report either
no or a hazardous effect.12e16
We hypothesized an interaction between bronchodilators
and smoking that may explain these discrepancies in safety
profiles.17 Through a change in hyperinflation and/or
breathing patterns, bronchodilators could affect COPD
patients’ smoking behavior e including both increased and
deeper smoke inhalation. Consequently, a more efficient
smokeexposure anda subsequent increase in smoke retention
could result in a modified risk profile to develop cigarette
smoke-related diseases like cardiovascular disease. Poten-
tially, this interaction might have implications in physicians’
decision making with regard to bronchodilator treatment in
COPDpatientswhopersist in their habit of smoking cigarettes.
Continuing our pilot study on interaction between
smoking and bronchodilation,18 the study reported in this
paper hypothesized that maximal bronchodilation would
increase the retention of cigarette smoke constituents,
such as tar and nicotine, in COPD patients who smoke
cigarettes, and consequently would increase biomarkers,
such as C-reactive protein and fibrinogen.
Methods
We conducted a randomized, double-blind, double-dummy,
placebo-controlled, crossover trial in patients with COPD,in which participants smoked cigarettes during both undi-
lated and maximal bronchodilated conditions. Study
methods have been ethically approved by the CMO region
Nijmegen-Arnhem (CMO 2009/037), registered at www.
clinicaltrials.gov (NCT00981851), and published in detail.19
Participants
COPD patients were recruited from respiratory clinics of
the Radboud University Nijmegen Medical Centre (RUNMC),
two neighboring general hospitals, and nine family prac-
tices. Selection criteria included: age 40e80 years; a diag-
nosis of COPD, GOLD stage 2 or 3,1 current smokers;
absence of interfering pulmonary diseases, including
asthma. Participants were advised on smoking cessation.
Interventions
Participants abstained from smoking and bronchodilators
according to a pre-specified schedule. In a designated
laboratory room of the RUNMC, participants smoked one
Coresta Monitor No. 6 (CM6) cigarette before and one after
inhalation of placebo aerosols in one session, and before
and after maximal bronchodilation in another session, with
one week between both sessions. During the measurements,
participants were instructed to smoke as they normally did.
Smoking conditions were standardized, including wearing
a nose clip, electrical cigarette ignition, smoking up to
32 mm from the filter end, and exhaling through Cambridge
filters. These filters trap 99.9% of particles larger than
100 nm, also referred to as tar (ISO 3308).20 CM6 cigarettes
were conditioned at 22 C and 60% relative humidity for at
least 2 days (ISO 3308). Maximal bronchodilation was ach-
ieved by two aerosol inhalers: 5 mg tiotropium Respimat,
and 400 mg salbutamol via Volumatic spacer.1
Outcomes and measurements
Changes of percentage of pulmonary retention of tar and
nicotine were the co-primary outcomes. The proportional
retention equals: (inhalation weight  exhalation weight)/
inhalationweight. Inhalationweightsof tar andnicotinewere
calculated from a regression model based on cigarette filter
nicotine weight analysis, including corrections from simul-
taneous blank filtermeasurements.19 As participants exhaled
through Cambridge filters, tar exhalation weights were
derived from filter weight increments after smoking, and
nicotine exhalation weights from their substance analyses.
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samples, smoke inhalation patterns from the Vivometrics
Lifeshirt, and pulmonary function by spirometry (Fig. 1).
Consequently, our secondary outcomes included: plasma C-
reactive protein and fibrinogen levels; smoke in- and exha-
lation volume and time; forced expiratory volume in one
second (FEV1) and forced volume capacity (FVC).
Sample size and randomization
Our statistician (RA) determined that in a crossover design
with paired samples, a number of 34 patients is sufficient to
demonstrate a pre and post mean difference of smoke
retention between undilated and bronchodilated smoking
conditions (assumptions: aZ 0.05, 1  bZ 0.80, two-tailed
testing, c Z 7.9): n Z c/d2 þ 2.21 We calculated a medium
standardized effect size (d) of 0.5, derived from a 10% stan-
dard deviation of smoke retention and a 5% increase of smoke
retention (as due to a 20% change of FVC).19 The medication
sequence was obtained by computer-generated block
randomizationwith a block size of 2. An independent research
nurse concealed allocation and secured double-blinding by
preparing identical active medication and placebo canisters.
Statistical analyses
Individual statistical differences between undilated and
bronchodilated smoking conditions were analyzed by linear
mixed models, including adjustments for potential learning
and carryover effects. As suspicions were raised of filter
contamination in eight sessions (their unused blank filters
showed positive measurements of nicotine), we performed
a secondary analysis without these sessions to control for
error by contamination. Furthermore, we analyzed the
effect of bronchodilation on biomarkers, smoke inhalation
patterns and pulmonary function. We evaluated associa-
tions between the level of smoke retention and the level of
obstruction, by Pearson’s correlation analyses, to test for
doseeeffect relationships. All analyses were performed in
SPSS 16.0. p-Values were set at 0.05 for statistical signifi-
cance testing, confidence intervals (CI) at 95%.
Results
Study population
Patients were recruited from October 2009 to March 2011.
Of 241 eligible candidates approached, we recruited 39Figure 1 Time schedule of experiment, including interven-
tions and measurements.patients for participation, of whom 35 (90%) completed the
study and were included in the final analyses (Fig. 2). Of 70
measurement sessions (each session includes one of the two
measurement sessions of one patient), 14 sessions had
missing values on nicotine exhalation due to values below
the limit of quantification, and 5 sessions showed negative
tar retentions (3% to 11%). Eight sessions suffered from
positive blanks, including 3 of the 5 sessions with negative
tar retentions.
Table 1 shows the baseline characteristics at randomi-
zation: 18 males (51%); mean (sd) age 59.5 years (8.8);
mean FEV1 1.74 l (0.53) or 60% (12) from predicted;
mean cumulative smoking exposure 37.3 packyears
(25.7). FEV1 and FVC both increased after bronchodilation
(FEV1 277 ml (11% from predicted), p < 0.001; FVC 200 ml,
p < 0.001) but not after placebo (FEV1 46 ml (2% from
predicted, p Z 0.13); FVC 50 ml, p Z 0.20). During 9
measurement sessions, patients were unable to properly
smoke because smoking provoked coughing fits or dysp-
noea. These coughing fits and dyspnoea resolved after the
intervention at 4 of 5 sessions with active bronchodilation
contrary to 1 of 4 sessions with placebos.
Effects on retention of smoke constituents
We observed mean (sd) pulmonary retentions of nicotine
and tar of 83% (16) and 53% (22), respectively, from
smoking prior to inhalation of any medication. Mean inha-
lation weights of tar and nicotine were 18.0 mg and 1.5 mg,
and did not statistically differ between the placebo or
bronchodilators sessions (p > 0.90). Linear mixed model
analysis revealed that bronchodilation did not increase tar
retention (4.5%, 95% CI Z 11.5% to 2.5%, p Z 0.20) or
nicotine retention (2.6%, 5.8% to 0.7%, pZ 0.11) (Tables
2 and 3, and Figs. 3 and 4). The secondary analysis that
controlled for contamination revealed a potential decrease
of tar and nicotine retentions: tar 3.8% (8.7% to 1.2%,
p Z 0.13), and nicotine 3.4% (5.9 to 0.8%, p Z 0.01).
Effects on biomarkers and smoke inhalation
patterns
Before smoking, mean (sd) high sensitivity-CRP was
7.65 mg/l (9.0) and mean (sd) fibrinogen was 4129 mg/l
(826). Mean (sd) inhalation and exhalation volumes and
times were 831 ml (652) and 1773 ml (1025), and 1.9 s
(0.78) and 5.3 s (1.7), respectively. Mean (sd) smoke
inhalation volumeeFVC ratio was 28% (18). Mean (sd)
smoking time and number of puffs were 7.1 min (1.4) and
12.7 puffs (2.9). We did not observe any statistical
differences in changes of biomarkers or smoke inhalation
patterns between the placebo aerosols and active bron-
chodilators sessions (Table 4).
Correlations on smoke retention and pulmonary
function
No correlation was found between level of airflow
obstruction and tar and nicotine retention. For both the
change in FVC and change in FEV1% from predicted we
observed a possible weak inverse correlation with change of
Figure 2 CONSORT flow chart of patients progressing through the randomized controlled crossover study.
Smoke retention and bronchodilation in COPD 115nicotine retention: Pearson’s r Z 0.25 (p Z 0.07) and
0.24 (p Z 0.07), respectively, and between change in
FEV1% from predicted and tar retention: 0.22 (p Z 0.08).
None of these reached statistical significance.Discussion
Our study did not confirm our hypothesis that bronchodi-
lation increases the pulmonary retention of cigarette
smoke as measured by tar and nicotine retention, nor could
we confirm that bronchodilation affects the smoke inhala-
tion pattern or smoking-related biomarkers. When
excluding the sessions with suspected contaminated filters,
we observed a potential decrease of smoke retentions.Table 1 Baseline demographic and clinical characteristics of
according to randomization.
Total (N Z 35)
Age (years) 59.5 (8.8)
Sex (male) 18 (51%)
Packyears 37.3 (25.7)
Pulmonary function
FEV1% (post BD) 60 (12)
Reversibilitya (%) 4.2 (4.4)
FVC (post BD) 3.61 (1.10)
FEV1/FVC (post BD) 0.50 (0.12)
TLC% 106 (16)
Diffusion (DLco)% 57 (15)
Cardiovascular disease 11 (31%)
Dichotomous variables are presented as total number (percentage), c
Packyears, calculated by former and current smoking habit; FEV1%, f
dicted; FVC, forced vital capacity (litre); TLC%, total lung capacity as
diffusing capacity as percentage from predicted; Cardiovascular disea
hypertension).
a Response on bronchodilator >10 min after administration.Several studies reported the effects of bronchodilators
on mortality, with varying results.12e16 However, these
trials usually suffered from methods not primarily designed
to study (cardiovascular) mortality and did not adjust for
the possible interaction between bronchodilators and
smoking. To the best of our knowledge, our study is the first
to address smoke retention in COPD patients and in
particular in relation to bronchodilation. The only studies
we found to compare our findings with, looked at cigarette
smoke retention in healthy subjects: with normal smoke
inhalation patterns, mean tar retention (50e80%) and mean
nicotine retention (90e100%) seem similar to our
results.22e27 These figures support our method to measure
smoke retention. Furthermore, for comparative purposes
smoking inhalation volumes are usually measured asthe 35 patients included in the study trial and analyzed,
Bronchodilation first
visit (N Z 20)
Placebo first
visit (N Z 15)
59.9 (8.2) 59.0 (9.8)
9 (45%) 9 (60%)
34.6 (20.1) 41.0 (32.1)
59 (13) 62 (12)
3.9 (4.6) 4.7 (4.1)
3.57 (1.26) 3.67 (0.88)
0.47 (0.12) 0.52 (0.10)
110 (18) 101 (11)
55 (16) 59 (13)
6 (30%) 5 (33%)
ontinuous variables as means (standard deviation).
orced expiratory volume in one second as percentage from pre-
percentage from predicted; Diffusion (DLco)%, carbon monoxide
se includes cardiac, cerebral en peripheral vascular disease (not
Table 2 Linear mixed model analysis for changes of
smoke retention due to medication, adjusted for learning
(visit) and carryover (sequence) effects.
Effect p-Value 95% CI
Primary analysis (35 patients, 70 sessions)
Change of tar retention
Intercept 2.8% 0.43 4.2% to 9.7%
Bronchodilation 4.5% 0.20 11.5% to 2.5%
Visit 0.5% 0.88 6.5% to 7.5%
Sequence 1.2% 0.73 8.2% to 5.8%
Change of nicotine retention
Intercept 6.3% 0.03a 0.6% to 11.9%
Bronchodilation 2.6% 0.11 5.8% to 0.7%
Visit 0.0% 0.99 3.2% to 3.3%
Sequence 5.2% 0.15 12.3% to 1.9%
Secondary analysis (35 patients, 62 sessions)
Change of tar retention
Intercept 2.3% 0.41 8.0% to 3.4%
Bronchodilation 3.8% 0.13 8.7% to 1.2%
Visit 0.1% 0.98 5.0% to 4.9%
Sequence 3.6% 0.26 2.8% to 10.1%
Change of nicotine retention
Intercept 2.0% 0.16 0.8% to 4.8%
Bronchodilation 3.4% 0.01a 5.9% to 0.8%
Visit 0.6% 0.62 1.9% to 3.2%
Sequence 0.7% 0.63 3.8% to 2.3%
a p-Value <0.05.
116 W.D. van Dijk et al.a proportion of the vital capacity. In healthy subjects,
previous studies revealed a smoking inhalation volume
similar to our results of around 25% of the vital
capacity,24,28,29 which indicates our method for measuring
smoke inhalation patterns is valid as well.
Strengths and limitations
Apart from our original hypothesis, the crossover design,
standardization, and baseline measurements of our
outcomes are important strengths. These methods
decreased variation and, consequently, reduced theTable 3 Mean smoke retentions before and after medication, c
Visit 1
Before medication After medic
Tar retention
Sequence A 57.2% 54.7% (BD)
Sequence B 48.3% 51.6% (P)
Nicotine retention
Sequence A 89.3% 88.9% (BD)
Sequence B 75.5% 82.3% (P)
Sequence A is first visit bronchodilators and second visit placebo; Sequnumber of patients needed for the study. Another strength
is that patients finished participation within a month and
hence our study would not have a significant impact on any
intermediate smoking cessation attempts. Furthermore, we
diminished cigarette variation by standardization and using
conditioned CM6 cigarettes, known for their minimal vari-
ability. In particular, we countered the variation of
between-patient differences in smoke inhalation and puff
patterns by the crossover design. In addition, we minimized
day-to-day variations by comparing individual smoke
retentions of cigarettes smoked on the same morning;
before and after medication. On the other hand, the
standardized settings like exhaling through Cambridge
filters may have interfered with the ‘natural’ smoking
behavior as participants seemed to exhale relatively long,
whereas the nose clips may have also modified inhalation
through affecting the patients’ sense of dyspnoea.
A possible limitation of our study was the fact that
smoking provoked cough and/or dyspnoea in a number of
patients. This may have interfered with our measurements,
and consequently with the findings on smoke reten-
tion.22,24,25 Problems in the measurement of tar and nico-
tine may have influenced the findings: we calculated
negative tar retentions (i.e., more tar exhaled than the
amount initially inhaled) in 5 sessions. These negative tar
retentions were accompanied by low nicotine retentions,
which suggest a possible mathematical error in the lower
retention ranges. In addition, we observed 14 sessions with
nicotine exhalation values below the limit of quantification,
reflecting a near 100% nicotine retention suggesting
possible underestimation of the mean nicotine retention
(83%) in our study. Another limitation is that our sample size
calculation was designed to detect a 5% change of smoke
retention, which makes it impossible to preclude effects
below this level.
The positive nicotine measurements of unused filter
blanks at several sessions need further explanation. If the
nicotine was derived from cigarette smoke, the nicotine
values of the positive blanks indicate an amount that would
have been visible as a change in the filter color. As filters
appeared blank on observation, the most likely explanation
is a laboratory-based contamination of the filters or extract
solutions with nicotine, for which no further clarification or
source could be found. According to ISO-standards one
should discard and recommence these measurements.
However, filters could not be analyzed again since their
contents were already fully extracted. We could notategorized by sequence and visit.
Visit 2
ation Before medication After medication
56.1% 57.6% (P)
46.3% 44.5% (BD)
85.6% 86.7% (P)
82.5% 83.4% (BD)
ence B vice versa; BD is after bronchodilators; P is after placebo.
Figure 3 Change of tar retention as modified by both bronchodilation and placebo. eeee are individual changes, whereas
d line is the mean change.
Smoke retention and bronchodilation in COPD 117conduct these measurements again and hence corrected
for these positive blanks with the assumption that the
contamination was similar for either all Cambridge filters or
all cigarette filters that were analyzed in the same batch. In
addition, we performed a secondary analysis that excluded
the sessions with possible systematic errors due to labora-
tory contamination. This secondary analysis did not confirm
an increase of smoke retention due to bronchodilation
either, but instead a possible decrease.
Finally, our study results cannot be directly translated to
all COPDpatients that persist in their smoking habit, althoughFigure 4 Boxplots for change of tar retention (%) from
smoking a cigarette, after administration of both bronchodi-
lator and placebo.our findings seem relevant for a substantial part of the COPD
population.7e9 Evenmore, our study aimwas to demonstrate
any existence of interaction, not generalization.
Interpretation
Our results do not confirm that bronchodilators in COPD
patients increase cigarette smoke retention, smoking-
related biomarkers or smoke inhalation patterns. Hence,
it would be unlikely that bronchodilators increase the risk
to develop cigarette smoke-related (cardiovascular)
diseases through these mechanisms. However, final smoke
exposure and translation into smoking-related cardiovas-
cular risk profiles depends on various factors, including the
number of cigarettes smoked, puff patterns, smoke inha-
lation patterns, and pulmonary smoke retention, penetra-
tion and transposition. Our study aimed to demonstrate
that bronchodilators in COPD patients who continue to
smoke might modify some of these factors, i.e., smoke
retention and smoke inhalation patterns. The effect of
bronchodilators on the other factors remains unclear and
further studies on the interactive effect in the general
COPD population and to what extent this interaction affects
final cardiovascular disease are needed to address this.
Further studies could add to a more deliberate prescription
of bronchodilators to COPD patients who persist in their
smoking habit, in particular those who already suffer from
cardiovascular disease.
In addition, different COPD phenotypes may be affected
differently by these factors of smoke exposure. Specifi-
cally, the possible effect of less smoke retention due to
bronchodilation as observed in our secondary analysis,
would be rather plausible in our cohort. Whilst the revers-
ibility of obstruction, as measured by FEV1% and FVC, might
be inversely correlated with smoke retention (near statis-
tical significance), this reversibility appeared higher in
patients that received bronchodilation, which may suggest
that reduction of obstruction may cause an improved
exhalation of hazardous smoke constituents and hence less
retention. More specific, air turbulence in the airways of
Table 4 The effect of bronchodilators on the secondary
outcomes of biomarkers and smoke inhalation patterns,
adjusted for both learning and carryover effects.
Effect p-Value 95% CI
Biomarkers
Hs-CRP (mg/l) 0.01 0.86 0.15 to 0.18
Fibrinogen (mg/l) 26 0.48 48 to 248
Smoke inhalation pattern
Inhalation volume (ml) 71 0.22 81 to 173
Exhalation volume (ml) 92 0.36 110 to 294
Inhalation time (s) 0.13 0.32 0.13 to 0.38
Exhalation time (s) 0.22 0.40 0.75 to 0.31
Smoking time (s) 13 0.37 16 to 41
Number of puffs 0.21 0.55 0.92 to 0.50
CI is confidence interval.
118 W.D. van Dijk et al.COPD patients may increase impaction and retention of
smoke constituents. Although in the current study bron-
chodilators did not affect smoke inhalation patterns, the
reduced obstruction could result in less turbulence and
deposition, resulting in less retention.
Conclusions
Our results suggest that the use of bronchodilators in COPD
patients that continue cigarette smoking is unlikely to
increase smoke retention. Moreover, we observed a trend
towards the opposite. As yet, there is a need to confirm our
findings in an independent study sample and on other risk
factors, and ultimately to study the effect of possible inter-
action on cigarette smoke-related (cardiovascular) diseases.
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